OUR SCIENCE
OUR SCIENCE

Agonist Redirected Checkpoint (ARC) Therapeutics for Cancer Immunotherapy and Inflammatory Disease.

Shattuck is developing a breakthrough platform for immunotherapy, which harnesses the human immune system to improve outcomes for patients battling cancer and inflammatory disease. Shattuck's proprietary technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple, synergistic functions.

learn more
OUR COMPANY
OUR COMPANY

Curious. Humble. Driven by Data.

We let science and data lead us, in all of our endeavors, always. We foster a company culture that strives to be humble, thoughtful, ever curious, and fun (because life is too short). Most of all, we feel privileged and lucky to be part of Shattuck, and to have the opportunity to contribute to science and ultimately to improve human health.

EXPLORE SHATTUCK
IN THE NEWS
IN THE NEWS
Taylor Schreiber to present at CD47/SIRPĪ± Summit

Presentation Title: Development and Characterization of SL-172154 (SIRPĪ±-Fc-CD40L) April 17th, 2019 at The Wyndham Beacon Hill - Boston, MA https://www.cd47sirpa.com/

Read more
Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology

Press Release 2017

Read more
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Fromm et.al Journal for ImmunoTherapy of Cancer, 18 December 2018

Read more